Spots Global Cancer Trial Database for ox40
Every month we try and update this database with for ox40 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | NCT04198766 | Solid Tumor Non-Small Cell ... Melanoma Head and Neck C... Gastric Cancer Renal Cell Carc... Urothelial Carc... | INBRX-106 - Hex... Pembrolizumab 2... Pembrolizumab 4... | 18 Years - | Inhibrx, Inc. | |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | NCT03336606 | Head and Neck C... Head and Neck S... Melanoma Cell Cancer, Sq... Carcinoma, Squa... | MEDI0562 | 18 Years - | Providence Health & Services | |
| Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | NCT01689870 | Metastatic Mela... | Anti-OX40 Ipilimumab | 18 Years - | Ludwig Institute for Cancer Research | |
| GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1) | NCT02528357 | Neoplasms | GSK3174998 Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors | NCT04730843 | Solid Tumors Neoplasms Malignant Tumor | ES102 | 18 Years - | Elpiscience Biopharma, Ltd. | |
| A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | NCT05263180 | Advanced Solid ... | EMB-09 | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | NCT03336606 | Head and Neck C... Head and Neck S... Melanoma Cell Cancer, Sq... Carcinoma, Squa... | MEDI0562 | 18 Years - | Providence Health & Services | |
| Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma | NCT05788107 | Solid Tumor, Ad... | HLX51 | 18 Years - | Shanghai Henlius Biotech | |
| A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | NCT02923349 | Advanced Malign... Metastatic Canc... | INCAGN01949 | 18 Years - | Incyte Corporation | |
| A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors | NCT04991506 | Solid Tumor Neoplasms Malignant Tumor | ES102 JS001 | 18 Years - | Elpiscience Biopharma, Ltd. | |
| A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | NCT02923349 | Advanced Malign... Metastatic Canc... | INCAGN01949 | 18 Years - | Incyte Corporation | |
| Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | NCT02315066 | Neoplasms | PF-04518600 PF-04518600 PF-04518600 plu... PF-04518600 plu... | 18 Years - | Pfizer | |
| Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | NCT04215978 | Advanced Solid ... Non Small Cell ... Head and Neck S... Nasopharyngeal ... | BGB-A445 tislelizumab | 18 Years - | BeiGene | |
| A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors | NCT04116710 | Advanced Solid ... | HS-110 (viagenp... HS-130 | 18 Years - | Heat Biologics | |
| A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors | NCT04991506 | Solid Tumor Neoplasms Malignant Tumor | ES102 JS001 | 18 Years - | Elpiscience Biopharma, Ltd. | |
| Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | NCT01689870 | Metastatic Mela... | Anti-OX40 Ipilimumab | 18 Years - | Ludwig Institute for Cancer Research | |
| A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | NCT05263180 | Advanced Solid ... | EMB-09 | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors | NCT02705482 | Select Advanced... | MEDI0562 Tremelimumab Durvalumab | 18 Years - 100 Years | MedImmune LLC | |
| A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors | NCT04116710 | Advanced Solid ... | HS-110 (viagenp... HS-130 | 18 Years - | Heat Biologics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
